Abstract
G-protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmitters and environmental stimulants, and so have great potential as therapeutic targets for a broad spectrum of diseases. They are also fascinating molecules from the perspective of membrane-protein structure and biology. Great progress has been made over the past three decades in understanding diverse GPCRs, from pharmacology to functional characterization in vivo. Recent high-resolution structural studies have provided insights into the molecular mechanisms of GPCR activation and constitutive activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. & Schioth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256–1272 (2003). This paper provides a comprehensive analysis of sequence relationships between G-protein-coupled receptors in the human genome.
Hoffman, B. B. & Lefkowitz, R. J. Adrenergic receptors in the heart. Annu. Rev. Physiol. 44, 475–484 (1982).
Samama, P., Pei, G., Costa, T., Cotecchia, S. & Lefkowitz, R. J. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol. Pharmacol. 45, 390–394 (1994).
Chidiac, P., Hebert, T. E., Valiquette, M., Dennis, M. & Bouvier, M. Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 45, 490–499 (1994).
Xiao, R. P., Cheng, H., Zhou, Y. Y., Kuschel, M. & Lakatta, E. G. Recent advances in cardiac beta(2)-adrenergic signal transduction. Circ. Res. 85, 1092–1100 (1999).
Shenoy, S. K. et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 281, 1261–1273 (2006).
Azzi, M. et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl Acad. Sci. USA 100, 11406–11411 (2003).
Freedman, N. J. & Lefkowitz, R. J. Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 51, 319–351; discussion 352–353 (1996).
Hanyaloglu, A. C. & von Zastrow, M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu. Rev. Pharmacol. Toxicol. 48, 537–568 (2008).
Terrillon, S. & Bouvier, M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5, 30–34 (2004).
Insel, P. A. et al. Caveolae and lipid rafts: G protein-coupled receptor signaling microdomains in cardiac myocytes. Ann. NY Acad. Sci. 1047, 166–172 (2005).
Ghanouni, P., Steenhuis, J. J., Farrens, D. L. & Kobilka, B. K. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc. Natl Acad. Sci. USA 98, 5997–6002 (2001).
Swaminath, G. et al. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279, 686–691 (2004).
Swaminath, G. et al. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280, 22165–22171 (2005).
Galandrin, S., Oligny-Longpre, G. & Bouvier, M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28, 423–430 (2007).
Wisler, J. W. et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl Acad. Sci. USA 104, 16657–16662 (2007).
Kobilka, B. K. & Deupi, X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28, 397–406 (2007).
Krebs, A., Villa, C., Edwards, P. C. & Schertler, G. F. Characterisation of an improved two-dimensional p22121 crystal from bovine rhodopsin. J. Mol. Biol. 282, 991–1003 (1998).
Schertler, G. F., Villa, C. & Henderson, R. Projection structure of rhodopsin. Nature 362, 770–772 (1993). This paper presents the first three-dimensional structure of a G-protein-coupled receptor using cryoelectron microscopy of two-dimensional crystals.
Rasmussen, S. G. et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450, 383–387 (2007). This is the first reported three-dimensional crystal structure of a ligand-activated G-protein-coupled receptor.
Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318, 1266–1273 (2007).
Cherezov, V. et al. High-resolution crystal structure of an engineered human β2-adrenergic G-protein-coupled receptor. Science 318, 1258–1265 (2007).
Hanson, M. A. et al. A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor. Structure 16, 897–905 (2008).
Warne, T. et al. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454, 486–491 (2008).
Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211–1217 (2008).
Palczewski, K. et al. Crystal structure of rhodopsin: A G-protein-coupled receptor. Science 289, 739–745 (2000). This paper presents the first three-dimensional crystal structure of a G-protein-coupled receptor, the visual photoreceptor rhodopsin.
Okada, T. et al. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J. Mol. Biol. 342, 571–583 (2004).
Li, J., Edwards, P. C., Burghammer, M., Villa, C. & Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343, 1409–1438 (2004).
Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. Methods Neurosci. 25, 366–428 (1995).
Shi, L. et al. β2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277, 40989–40996 (2002).
Horn, F. et al. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res. 31, 294–297 (2003).
Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41–54 (2009).
Baker, J. G. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br. J. Pharmacol. 144, 317–322 (2005).
Sugimoto, Y. et al. β1-selective agonist (-)-1-(3,4-dimethoxyphenetylamino)-3-(3,4-dihydroxy)-2-propanol [(-)-RO363] differentially interacts with key amino acids responsible for β1-selective binding in resting and active states. J. Pharmacol. Exp. Ther. 301, 51–58 (2002).
Vogel, R. et al. Functional role of the “ionic lock”—an interhelical hydrogen-bond network in family A heptahelical receptors. J. Mol. Biol. 380, 648–655 (2008).
Ballesteros, J. A. et al. Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276, 29171–29177 (2001).
Rasmussen, S. G. et al. Mutation of a highly conserved aspartic acid in the β2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol. Pharmacol. 56, 175–184 (1999).
Yao, X. et al. Coupling ligand structure to specific conformational switches in the β2-adrenoceptor. Nature Chem. Biol. 2, 417–422 (2006).
Bond, R. A. & Ijzerman, A. P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27, 92–96 (2006).
Barak, L. S., Menard, L., Ferguson, S. S., Colapietro, A. M. & Caron, M. G. The conserved seven-transmembrane sequence NP(X)2,3Y of the G-protein-coupled receptor superfamily regulates multiple properties of the β2-adrenergic receptor. Biochemistry 34, 15407–15414 (1995).
Okada, T. et al. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl Acad. Sci. USA 99, 5982–5987 (2002).
Pardo, L., Deupi, X., Dolker, N., Lopez-Rodriguez, M. L. & Campillo, M. The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. ChemBioChem 8, 19–24 (2007).
Dixon, R. A. et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature 321, 75–79 (1986). This paper reports the cloning of the first ligand-activated G-protein-coupled receptor.
Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H. W. & Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183–187 (2008).
Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502 (2008). This paper presents the high-resolution stucture of an active-state G-protein-coupled receptor in complex with a G-protein peptide.
Lamb, T. D. & Pugh, E. N. Jr. Dark adaptation and the retinoid cycle of vision. Prog. Retin. Eye Res. 23, 307–380 (2004).
Vogel, R. & Siebert, F. Conformations of the active and inactive states of opsin. J. Biol. Chem. 276, 38487–38493 (2001).
Cohen, G. B., Oprian, D. D. & Robinson, P. R. Mechanism of activation and inactivation of opsin: role of Glu113 and Lys296. Biochemistry 31, 12592–12601 (1992).
Ahuja, S. et al. Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. Nature Struct. Mol. Biol. 16, 168–175 (2009).
Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L. & Khorana, H. G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274, 768–770 (1996). This is the first biophysical study to demonstrate movement of transmembrane segment 6 upon activation of rhodopsin.
Altenbach, C., Kusnetzow, A. K., Ernst, O. P., Hofmann, K. P. & Hubbell, W. L. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc. Natl Acad. Sci. USA 105, 7439–7444 (2008).
Strader, C. D., Candelore, M. R., Hill, W. S., Sigal, I. S. & Dixon, R. A. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264, 13572–13578 (1989).
Liapakis, G. et al. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the β2-adrenergic receptor. J. Biol. Chem. 275, 37779–37788 (2000).
Strader, C. D. et al. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263, 10267–10271 (1988).
Jiang, Q., Lee, B. X., Glashofer, M., van Rhee, A. M. & Jacobson, K. A. Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J. Med. Chem. 40, 2588–2595 (1997).
Patny, A., Desai, P. V. & Avery, M. A. Homology modeling of G-protein-coupled receptors and implications in drug design. Curr. Med. Chem. 13, 1667–1691 (2006).
Kolb, P. et al. Structure-based discovery of β2-adrenergic receptor ligands. Proc. Natl Acad. Sci. USA 106, 6843–6848 (2009).
Ghanouni, P. et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor. J. Biol. Chem. 276, 24433–24436 (2001).
Salom, D. et al. Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc. Natl Acad. Sci. USA 103, 16123–16128 (2006).
Knierim, B., Hofmann, K. P., Ernst, O. P. & Hubbell, W. L. Sequence of late molecular events in the activation of rhodopsin. Proc. Natl Acad. Sci. USA 104, 20290–20295 (2007).
De Lean, A., Stadel, J. M. & Lefkowitz, R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 7108–7117 (1980).
Hubbell, W. L., Altenbach, C., Hubbell, C. M. & Khorana, H. G. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 63, 243–290 (2003).
Werner, K., Richter, C., Klein-Seetharaman, J. & Schwalbe, H. Isotope labeling of mammalian GPCRs in HEK293 cells and characterization of the C-terminus of bovine rhodopsin by high resolution liquid NMR spectroscopy. J. Biomol. NMR 40, 49–53 (2008).
Standfuss, J. et al. Crystal structure of a thermally stable rhodopsin mutant. J. Mol. Biol. 372, 1179–1188 (2007).
Okada, T. et al. X-ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. J. Struct. Biol. 130, 73–80 (2000).
Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877–882 (2008).
Day, P. W. et al. A monoclonal antibody for G protein-coupled receptor crystallography. Nature Methods 4, 927–929 (2007).
Faham, S. & Bowie, J. U. Bicelle crystallization: a new method for crystallizing membrane proteins yields a monomeric bacteriorhodopsin structure. J. Mol. Biol. 316, 1–6 (2002).
Faham, S. et al. Crystallization of bacteriorhodopsin from bicelle formulations at room temperature. Protein Sci. 14, 836–840 (2005).
Caffrey, M. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. Annu. Rev. Biophys. 38, doi:10.1146/annurev.biophys.050708.133655 (2008).
Acknowledgements
This work was supported by the US National Institute of General Medical Sciences (grant F32 GM082028 to D.M.R. and grant RO1-GM083118 to B. K.), the Lundbeck Foundation (to S.G.F.R.), the National Institute of Neurological Disorders and Stroke (grant RO1-NS28471 to B.K.) and the Mather Charitable Foundation (to B. K.).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Reprints and permissions information is available at http://www.nature.com/reprints.
Correspondence should be addressed to B.K.K. (kobilka@stanford.edu).
Rights and permissions
About this article
Cite this article
Rosenbaum, D., Rasmussen, S. & Kobilka, B. The structure and function of G-protein-coupled receptors. Nature 459, 356–363 (2009). https://doi.org/10.1038/nature08144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature08144
This article is cited by
-
A method for structure determination of GPCRs in various states
Nature Chemical Biology (2024)
-
Molecular mechanisms underlying the signal perception and transduction during seed germination
Molecular Breeding (2024)
-
Structure, function and drug discovery of GPCR signaling
Molecular Biomedicine (2023)
-
Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
European Journal of Medical Research (2023)
-
An insight into the functional genomics and species classification of Eudiplozoon nipponicum (Monogenea, Diplozoidae), a haematophagous parasite of the common carp Cyprinus carpio
BMC Genomics (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.